More than half of men receiving high-dose-rate brachytherapy for localized prostate cancer report some side effects that in some cases persist for up to 16 years
ATLANTAMore than half of men receiving high-dose-rate brachytherapy for localized prostate cancer report some side effects that in some cases persist for up to 16 years, according to a retrospective analysis. Sven Henrik Stbinger, MD, of the University Hospital Kiel, Germany, presented the results at the American Urological Association 101st Annual Meeting (abstract 1137).
Surveys were offered to 805 men who were treated with external percutaneous radiation (70 Gy) and dose-escalating high-dose-rate brachytherapy between 1986 and 2002. Men either filled out questionnaires or were interviewed by phone. In survey results from 510 men, the most common short-term side effects included various voiding dysfunctions and diarrhea, including leakage (17%), alguria (14%), diarrhea (13%), and residual urine (12%). Late-onset side effects included proctitis (10%), incontinence (6%), urethral stricture (5%), cystitis (3%), stool incontinence (3%), fistula (1%), and urinary retention (1%).
Of the 299 men who provided information on potency, 33% reported erectile dysfunction that had developed since their treatment. "It is very difficult in a retrospective style to get information from patients before the treatment," Dr. Stbinger said at a press briefing. He noted that these retrospective results do give an idea of what clinicians, researchers, and patients might expect.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.